Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intech Biopharm Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Intech Biopharm's Operating Margin % or its related term are showing as below:
ROCO:6461'
s Operating Margin % Range Over the Past 10 Years
Min: -1796.37 Med: -1189.83 Max: -338.99
Current: -338.99
ROCO:6461's Operating Margin % is ranked worse than 65.5% of 939
companies
in the Biotechnology industry
Industry Median: -86.33
vs ROCO:6461: -338.99
Intech Biopharm's 5-Year Average Operating Margin % Growth Rate was 14.90% per year.
Intech Biopharm's Operating Income for the
three
months ended in Dec. 2025 was NT$-120.4 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-364.5 Mil.
Warning Sign:
Intech Biopharm Ltd has never been profitable in the past 3 years. It lost money every year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Intech Biopharm Operating Margin % Related Terms
Intech Biopharm Operating Margin % Historical Data
* Premium members only.
The historical data trend for Intech Biopharm's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6461 vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Intech Biopharm's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intech Biopharm Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intech Biopharm's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Intech Biopharm's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Intech Biopharm's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Margin % of -2,495.81% mean?
Intech Biopharm (ROCO:6461) has a Operating Margin % of -2,495.81% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Intech Biopharm and its competitors. According to the industry distribution chart, Intech Biopharm ranks #615 out of 939 companies in the Biotechnology industry, placing it in the top 65.5%.
Is Intech Biopharm's Operating Margin % too high?
Intech Biopharm's current Operating Margin % is -2,495.81%. Based on the distribution chart, Intech Biopharm ranks #615 out of 939 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intech Biopharm has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Intech Biopharm's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intech Biopharm ranks #615 out of 939 companies for Operating Margin %. This places Intech Biopharm in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Intech Biopharm and its competitors. Intech Biopharm's current Operating Margin % is -2,495.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intech Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Intech Biopharm (ROCO:6461) is currently considered Possible Value Trap. The stock's GF Value™ is NT$87.86, compared to a current price of NT$15.45 — trading 82.4% below its estimated fair value. The current Operating Margin % is -2,495.81%. Intech Biopharm's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Intech Biopharm (ROCO:6461), the current Operating Margin % is -2,495.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intech Biopharm (ROCO:6461) Overvalued in 2026?
Based on GuruFocus' analysis, Intech Biopharm stock appears to be undervalued.
The current stock price of NT$15.45 is trading 82.4% below its estimated GF Value™ of NT$87.86.
GuruFocus considers Intech Biopharm to be Possible Value Trap.
Key valuation signals for ROCO:6461:
Operating Margin %: -2,495.81%
GF Value™: NT$87.86 vs. price of NT$15.45 (82.4% below fair value)
No single metric tells the full story. See the ROCO:6461 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intech Biopharm Ltd is engaged in pharmaceutical R&D and sales. The company focuses on the development and manufacturing of new combinations, new formulations, and generic drugs with high barriers for the treatment of respiratory diseases. It owns the patented MDI platform iLEF (Inhaled Low Ethanol Formulation). The company operates in a single-industry segment, mainly engaged in R&D of technology and sale of pharmaceuticals.
55GF Score
Get the complete analysis for ROCO:6461
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6461 has been successfully added to your 
